JMIR Publications

ABSTRACT

Background:

Mobile health applications (apps) are increasing in interest for enhancing patient self-management in rheumatology. Inflammatory arthritis (IA) represents painful chronic conditions impairing quality of life, for which disease-modifying anti-rheumatic drugs (DMARDs) are used to control disease activity and reduce functional disability. DMARDs are increasing in availability (>15 DMARDs in France) and have a wide variety of targets and modes of administration, but their use is associated with risk of adverse effects such as infections. Few apps in rheumatology have been developed with the involvement of patients and health professionals (HPs) and are actually used by patients. Patient education, including e-education, is advocated to improve patients’ autonomy over their own health. Apps may be appropriate tools for self-managing medications, problem-solving or care coordination.

Objective:

To develop a self-management mobile app for patients with IA by using a user-centred step-by-step approach and assess its real-life use.

Methods:

The development was promoted by the French Society of Rheumatology. A mixed-method qualitative–quantitative study including 42 and 344 patients, respectively, identified the impact of IA on daily life, patients’ treatments practices, social relationships, use of health apps and potential use needs. A multidisciplinary team including 7 rheumatologists, 3 patient association representatives and 5 members of a digital company developed the first version of the app via face-to-face meetings and patient feedback during the process. After launch, 2 in-depth users’ tests including 13 patients and 3 rheumatologists led to the app’s current version. The number of app installations, current users, and user requests were collected, as were scores and comments at stores.

Results:

The qualitative study revealed needs for information and counselling, development of a HP–patient partnership, development of skills to cope with daily life and risk situations with treatment aids; 86.8% participants in the quantitative study would be ready to use an app primarily on their rheumatologist’s recommendation. Six functionalities were implemented: a safety checklist before treatment administration, aids in daily life situations, treatment reminders, global well-being self-assessment, periodic counselling messages, and a diary. Aids for risk situations were based on the French academic recommendations for DMARD management, drug leaflets and websites of national health authorities. The app is free, with no personal data collection. The presentation is a “companion” called Hiboot (“owl” in English). Hiboot was installed 20,500 times from 2017 to 2020, with 4300 regular current users and still-increasing usage curves. Overall, 18,000 requests on treatment self-management were identified over an 8-month period in 2020. Scores were 4.4/5 stars at Android and iOS stores.

Conclusions:

Hiboot is a free self-management app for patients with inflammatory arthritis developed by a step-by-step process including patients and HPs. The number of current users is substantial. Further evaluation of the Hiboot benefit is needed.